Trial investigator Emma Guttman, MD, PhD, chair of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, here explains why targeting the OX40-OX40 ligand pathway is so exciting ...

A position paper argues that any systemic corticosteroid exposure in atopic dermatitis should trigger a transition to ...

Coconut oil can reduce dandruff severity and fight yeast, benefiting dry scalps with its antifungal properties. However, it ...

A retrospective chart review finds that Black patients with atopic dermatitis report fewer dupilumab-associated adverse ...

Perioral dermatitis is a skin condition that can make you feel frustrated and confused at the same time, causing red bumps, ...

Nektar Therapeutics still needs to establish what differentiates rezpeg from other atopic dermatitis therapies, according to ...

The FDA has expanded the approval of Opzelura to include patients 2 to 11 years of age for treatment of mild to moderate atopic dermatitis.

The FDA approved a supplemental new drug application for ruxolitinib cream 1.5% for the short-term and noncontinuous ...

Lice cannot hop, jump or fly. The most common way to get lice is through head-to-head contact with someone who already has ...

Ruxolitinib cream received an expanded approval to treat patients as young as 2 years old with non-immunocompromised mild to severe atopic dermatitis. Ruxolitinib cream (Opzelura; Incyte), a topical ...

Early onset atopic dermatitis and food allergy, among other factors, indicate greater risk for moderate to severe asthma in ...